Researchers have long known that the Wharton's jelly layer of the umbilical cord is an incredibly rich source for the growth factors needed to regenerate tissue. While the Wharton’s jelly layer of the umbilical cord can be easily procured, it is extremely difficult to process effectively. That’s where Predictive prides itself most; we use a proprietary method that minimally processes the tissue in order to preserve maximum integrity of the tissue. In fact, we’re the first and only company in the world to develop a suite of products derived from Wharton’s jelly, currently the subject of an IND application for treatment of osteoarthritis of the knee, thus leading the field.
Standards that matter.
Predictive Biotech is committed to truth, trust, and transparency. We set high standards and hold ourselves to them by being honest with our clients, being meticulous with our processing, and ensuring the integrity of every product. It's a better way to treat people—and it starts here.
Science and standards to live by.
Predictive's vision is simple: convert cutting-edge research in human biology to products that can repair or replace the natural environment in everybody. The promise of regenerative medicine is revealing itself every day as research and application grow, but navigating new companies in the market can be hard, especially if they have not kept up with the science or shown a commitment to setting or meeting standards. To fulfill our vision and more importantly to connect it with patients and clinicians, Predictive Biotech follows an all-encompassing ethos of truth, trust, and transparency. This means that we hold ourselves to the highest standards of product development, product communication, regulatory compliance, and safety. Period.
What makes our products valuable? Integrity.
By preserving the natural components of the tissue as it is harvested and transferred to the patient, we can better ensure the integrity of the allograft. Our single-minded focus on minimizing tissue degradation shows in our careful procurement and minimal processing in our own FDA-registered lab.
Setting standards: from donor to doctor to patient.
From donation to administration, Predictive Biotech is unwavering in its commitment to perfecting each and every step. All of our IND allograft products are prepared through a proprietary process. After processing, each lot is screened for bacterial and viral contamination, and placed into quarantine.
Our wound care line of products including AmnioBind™ is terminally sterilized using gamma irradiation.
Once all quality and safety testing has been completed and all the paperwork has been reviewed and approved by our Chief Medical Officer, then - and only then - are our products cleared.
Our Human Cell and Tissue Products (HCT/Ps) are not FDA approved or licensed for the prevention, treatment, diagnosis, mitigation and/or cure of any disease or condition, including COVID-19.